References
- Bayer Yakuhin LTD. 2021. Verquvo® tablets 2.5 mg/5 mg/10 mg. 2021. [accessed February 9, 2022].
- Becker C, Boettcher M, Loewen S, Mueck W. 2019. Biopharmaceutical profile, bioavailability, food effect, and pharmacokinetics of vericiguat: a novel soluble guanylate cyclase stimulator. The American Association of Pharmaceutical Scientists (AAPS). 60:337–351.
- Benet LZ, Galeazzi RL. 1979. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 68(8):1071–1074.
- Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M, Lemmen J, Mueck W, Radtke M, Becker C. 2020. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase I healthy volunteer studies. Clin Pharmacokinet. 59(11):1407–1418.
- Charter MK. 1989. The estimation of moments: a technical note. J Pharmacokinet Biopharm. 17(2):203–208.
- European Medicines Agency. VerquvoTM summary of product characteristics. [updated 07/2021; accessed October 6, 2021]. https://www.ema.europa.eu/en/documents/product-information/verquvo-epar-product-information_en.pdf.
- Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, et al. 2017. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 60(12):5146–5161.
- Food and Drug Administration. 2018. Bioanalytical method validation - guidance for industry. [accessed March 22, 2019]. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
- Food and Drug Administration. 2021. VerquvoTM (vericiguat) tablets. Highlights of prescribing information. [accessed 2021 Feb 08]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf.
- Kaivosaari S, Finel M, Koskinen M. 2011. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 41(8):652–669.
- Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, Roessig L, Stasch JP. 2021. Soluble GC stimulators and activators: past, present and future. Br J Pharmacol. 2021:1–22. Online ahead of print.
- Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. 2003. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos. 31(3):326–333.
- Soars MG, Riley RJ, Findlay KAB, Coffey MJ, Burchell B. 2001. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos. 29(2):121–126.
- Troberg J, Jarvinen E, Muniz M, Sneitz N, Mosorin J, Hagstrom M, Finel M. 2015. Dog UDP-glucuronosyltransferase enzymes of subfamily 1A: cloning, expression, and activity. Drug Metab Dispos. 43(1):107–118.
- van Groen BD, Nicolaï J, Kuik AC, Van Cruchten S, van Peer E, Smits A, Schmidt S, de Wildt SN, Allegaert K, De Schaepdrijver L, et al. 2021. Ontogeny of hepatic transporters and drug-metabolizing enzymes in humans and in nonclinical species. Pharmacol Rev. 73(2):597–678.
- Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 6(6):547–558.
- Zimmer DP, Shea CM, Tobin JV, Tchernychev B, Germano P, Sykes K, Banijamali AR, Jacobson S, Bernier SG, Sarno R, et al. 2020. Olinciguat, an oral sGC stimulator, exhibits diverse pharmacology across preclinical models of cardiovascular, metabolic, renal, and inflammatory disease. Front Pharmacol. 11:419.